Manuel de Lera Ruiz, Principal Scientist in Discovery Chemistry at Merck, will deliver a seminar entitled, "From Orphan Phenotypic Screening Hit to MK-7602: Invention of a Novel Dual-Action Antimalarial Drug Candidate through an Effective Industry- Academia Collaboration." Hosted by Tania Lupoli.
Bio: Manuel de Lera Ruiz received his B.Sc. in Organic Chemistry from the Universidad Autónoma of Madrid in 1997. After completion of his Ph.D. in 2001 from the University of Nottingham, U.K. he joined Professor Leo A. Paquette research labs at Ohio State University as a postdoctoral fellow. In 2003, he started a career in Medicinal Chemistry at Schering-Plough Research Institute in New Jersey. Manuel moved to Merck's West Point site in 2012 where he worked for three and a half years in Discovery Process Chemistry. In 2016 he moved back to medicinal chemistry at West Point where he is currently a Principal Scientist in Discovery Chemistry co-leading the Malaria plasmepsin inhibitors program.